Renal biopsies should be performed whenever treatment strategies depend on renal involvement

We read with great interest the European League Against Rheumatism/European Renal Association–European Dialysis and Transplant Association guidelines for the management of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV).1 We strongly support the recommendation of performing a renal biopsy whenever a renal involvement is suspected as the only organ-threatening or life-threatening manifestation. Indeed, we came across several cases of different diseases presenting as AAV which support this recommendation, as exemplified below.

An 18-year-old woman self-presented to the emergency department (ED) with abdominal pain, diarrhoea, gross haematuria and fever for the last 5 days. In ED, blood test was normal (serum creatinine (SCr) at 71 μmol/L (0.8 mg/dL) and normal blood count) except C reactive protein at 30 mg/L, and urinary test showed haematuria (100 red blood cells/μL) with protein-to-creatinine ratio of 1g/g. She was referred to the nephrology department 3 days later.

SCr had increased to 124 μmol/L (1.4 mg/dL) and the results of the ANCA were strongly positive with a cytoplasmic fluorescence (>1/200) and an anti-proteinase 3 specificity (187 U/mL). In front of this rapidly progressive glomerulonephritis with ANCA positivity, the diagnosis of AAV was strongly suspected and we performed an ultrasound-guided transcutaneous renal biopsy followed by three methylprednisolone pulses. The immunofluorescence microscopy revealed diffuse mesangial IgA fluorescence with less intense C3 codeposition. Light microscopy showed expansion of the mesangial matrix without hypercellularity, intratubular erythrocytic casts and no glomerular crescents. This was consistent with the diagnosis of IgA nephropathy with an M0E0S0T0(C0) MEST score (Mesangial hypercellularity, Endocapillary hypercellularity, Segmented glomerulosclerosis, Tubular atrophy/interstitial fibrosis (Crescent)). Acute renal failure was attributed to the intratubular erythrocytic casts and SCr indeed decreased in the following days in spite of a cessation of immunosuppressive drugs. One month later, her blood pressure was normal (124/66 mm Hg), proteinuria was not significant anymore (0.11 g/g) and SCr was 80 μmol/L (0.9 mg/dL). Six months thereafter she was free of any kidney disease manifestation and we discarded the diagnosis of AAV as she had never demonstrated any extrarenal manifestation. The discontinuation of immunosuppressive treatment in this patient was only permitted by the result of the renal biopsy. In addition, Vrtovsnik et al2 reported the case of a patient with simultaneous IgA nephropathy and granulomatosis with polyangiitis (formerly Wegener’s granulomatosis) confirming that even when AAV is confirmed urinary abnormalities may be related to another renal disease, which may change the treatment strategy. Therefore, we would recommend the performance of renal biopsy when kidney impairment is the only organ-threatening or life-threatening manifestation even when AAV was proven.

Gillian Divard,1 Aurelie Sannier,2 Guillaume Hanouna,1,3 Eric Daugas,1,3 Francois Vrtovsnik,1,3 Jonathan M Chemouny1,3

1Department of Nephrology, Bichat-Claude Bernard Hospital, DHU Fire, AP-HP, Paris, France
2Department of Pathology, Bichat-Claude Bernard Hospital, DHU Fire, AP-HP, Paris, France
3Paris Diderot-Paris 7 University, Paris, France

Correspondence to Dr Jonathan M Chemouny, Hopital Bichat-Claude Bernard, DHU Fire, AP-HP, 46 rue Henri Huchard, Paris 75018, France; jonathan.chemouny@aphp.fr

Competing interests None declared.

Provenance and peer review Not commissioned; internally peer reviewed.

Received 7 December 2016
Accepted 10 December 2016
Published Online First 25 January 2017


REFERENCES
Renal biopsies should be performed whenever treatment strategies depend on renal involvement

Gillian Divard, Aurelie Sannier, Guillaume Hanouna, Eric Daugas, Francois Vrtovsknik and Jonathan M Chemouny

*Ann Rheum Dis* 2017 76: e27 originally published online January 25, 2017
doi: 10.1136/annrheumdis-2016-210933

Updated information and services can be found at:
[http://ard.bmj.com/content/76/8/e27](http://ard.bmj.com/content/76/8/e27)

These include:

**References**

This article cites 2 articles, 1 of which you can access for free at:
[http://ard.bmj.com/content/76/8/e27#BIBL](http://ard.bmj.com/content/76/8/e27#BIBL)

**Email alerting service**

Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

**Notes**

To request permissions go to:
[http://group.bmj.com/group/rights-licensing/permissions](http://group.bmj.com/group/rights-licensing/permissions)

To order reprints go to:
[http://journals.bmj.com/cgi/reprintform](http://journals.bmj.com/cgi/reprintform)

To subscribe to BMJ go to:
[http://group.bmj.com/subscribe/](http://group.bmj.com/subscribe/)